Connection

Co-Authors

This is a "connection" page, showing publications co-authored by MICHAEL FRUMOVITZ and ANIL K SOOD.
Connection Strength

2.098
  1. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol. 2007 Mar; 104(3):768-78.
    View in: PubMed
    Score: 0.291
  2. Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer. Obstet Gynecol. 2023 05 01; 141(5):1019-1023.
    View in: PubMed
    Score: 0.222
  3. Editor's Note: Targeting Src in Mucinous Ovarian Carcinoma. Clin Cancer Res. 2021 08 01; 27(15):4450.
    View in: PubMed
    Score: 0.198
  4. Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma. Obstet Gynecol. 2019 12; 134(6):1253-1259.
    View in: PubMed
    Score: 0.176
  5. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther. 2019 01; 18(1):162-172.
    View in: PubMed
    Score: 0.163
  6. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecol Oncol. 2014 Jul; 134(1):6-9.
    View in: PubMed
    Score: 0.121
  7. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43.
    View in: PubMed
    Score: 0.115
  8. Unverifiable accomplishments and publications on applications for gynecologic oncology fellowships. Obstet Gynecol. 2012 Mar; 119(3):504-8.
    View in: PubMed
    Score: 0.103
  9. Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res. 2011 Aug 15; 17(16):5367-78.
    View in: PubMed
    Score: 0.098
  10. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010 Jun; 117(3):491-6.
    View in: PubMed
    Score: 0.090
  11. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010 Feb 01; 116(3):625-30.
    View in: PubMed
    Score: 0.089
  12. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3.
    View in: PubMed
    Score: 0.070
  13. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol. 2024 05; 230(5):544.e1-544.e13.
    View in: PubMed
    Score: 0.059
  14. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol. 2023 06; 228(6):724.e1-724.e9.
    View in: PubMed
    Score: 0.055
  15. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.050
  16. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546.
    View in: PubMed
    Score: 0.043
  17. Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases. Gynecol Oncol. 2019 01; 152(1):101-105.
    View in: PubMed
    Score: 0.041
  18. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
    View in: PubMed
    Score: 0.040
  19. Proceedings from the 9th International Conference on Ovarian Cancer. Gynecol Oncol. 2012 Apr; 125(1):5-7.
    View in: PubMed
    Score: 0.025
  20. Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes. Gynecol Oncol. 2012 Apr; 125(1):252-5.
    View in: PubMed
    Score: 0.025
  21. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010 Aug; 116(2 Pt 1):269-273.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.